University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

January 2012

cHYD1 Solution Phase Synthesis Optimization
and the Development of a Novel Human Growth
Hormone Antagonist and Agonist
Philip Murray
University of South Florida, pmurray3@mail.usf.edu

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons, and the Chemistry Commons
Scholar Commons Citation
Murray, Philip, "cHYD1 Solution Phase Synthesis Optimization and the Development of a Novel Human Growth Hormone
Antagonist and Agonist" (2012). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/4179

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

cHYD1 Solution Phase Synthesis Optimization and the Development of
a Novel Human Growth Hormone Antagonist and Agonist

by

Philip Murray

A thesis submitted in partial fulfillment
of the requirement for the degree of
Doctor of Philosophy
Department of Chemistry
College of Arts and Sciences
University of South Florida

Major Professor: Mark McLaughlin, Ph.D.
Wayne Guida, Ph.D.
Mohanraja Kumar, Ph.D.
Thomas Jackman, Ph.D.
Date of Approval:
April 4, 2012

Keywords: Cyclic Peptides, Beta Hairpins, Molecular Modeling,
Peptidomimetics, Orthogonal Protecting Schemes
Copyright © 2012 Philip Murray

ACKNOWLEDGEMENTS
I would like to thank my parents, Bob and Suzan Murray, and my
sister, Sasha Murray, for providing the support and drive needed to
pursue my doctorate degree. I would like to thank Dr. Mark
McLaughlin for bringing me into his lab, giving me a chance, and
sticking with me all the way to the end and then some, while imparting
a lifetime of invaluable knowledge. I cannot thank him enough for this
opportunity. I would like to thank Dr. Priyesh Jain, who has helped me
immensely in getting through every hurdle and stumbling block along
the way and helping me learn and understand peptide and synthetic
organic chemistry. I would like to thank my committee members Dr.
Wayne Guida, Dr. Mohanraja Kumar, and Dr. Thomas Jackman for
guiding me through this entire doctorate process. I would also like to
thank Dr. Ted Gauthier for initially teaching me solid phase peptide
chemistry and characterization, as well as a lifetime of knowledge in
running an analytical chemistry facility. I would like to thank Daniel
Santiago for his help with the molecular modeling studies. I would like
to thank David Badger for his help in the NMR studies, and keeping
things light-hearted in the lab. I would like to thank Hyun Joo Kil for

her help with the peptide synthesis project and collection of data. I
would like to thank Mike Doligalski for help in MALDI data collection. I
want to thank the rest of Dr. McLaughlin’s group: Dr. Sridhar
Kaulagari, Yi Liang, Josanne-Dee Woodroffe, and Fenger Zhou. I
cannot go without thanking Ed Brennan, Jimi Kiner, Ryan Gober, and
the entire University of Tampa Swim Team in allowing me to coach the
sport that I love and has given me so much while pursuing this
degree, providing a tremendous amount of support throughout this
entire process. Finally, I would like to thank the H. Lee Moffitt Cancer
Center and Research Institute as well as the Department of Chemistry
at the University of South Florida for providing me the support and
facilities to perform my work.

TABLE OF CONTENTS

LIST OF TABLES ........................................................................... v

LIST OF FIGURES ........................................................................ vi

LIST OF SCHEMES ........................................................................ x

ABSTRACT .................................................................................. xi

CHAPTER ONE: INTRODUCTION ..................................................... 1
1.1 Peptide and protein overview ........................................... 1
1.2 Secondary Structures ..................................................... 5
1.3 Peptidomimetics ........................................................... 10
1.3.1 Cyclic Peptidomimetics ....................................... 12
1.4 Solid Phase And Solution Phase Synthesis ....................... 15
1.5 Protecting Groups ......................................................... 18
1.5.1 Orthogonal Protecting Schemes .......................... 21
1.6 Coupling Agents ........................................................... 22
1.7 References .................................................................. 27
i

CHAPTER TWO: cHYD1 SOLUTION PHASE SYNTHESIS
OPTIMIZATION .................................................................. 29
2.1 Introduction................................................................. 29
2.1.1 Solution Phase Synthesis Strategy....................... 33
2.1.2 Coupling Agents ................................................ 35
2.2 Linker Development ...................................................... 36
2.2.1 Tert-butyl-2-aminoethylcarbamate ...................... 36
2.2.2 Tert-butyl (2(methylsulfonamido)ethyl)carbamate ........................... 37
2.2.3 Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)aceta
te, Boc-Linker(OMe)................................................... 38
2.2.4 Linker Deprotection ........................................... 39
2.3 Amino Acid Coupling ..................................................... 41
2.3.1 Dimer Synthesis ................................................ 42
2.3.1.1 Dimer Purification .................................. 44
2.3.1.2 Dimer Yield ........................................... 44
2.3.2 Cbz Deprotection............................................... 45
2.3.3 Subsequent Amino Acid Couplings ....................... 47
2.4 Future Considerations ................................................... 48
2.5 Experimental Procedure ................................................ 49
2.5.1 Tert-butyl-2-aminoethylcarbamate ...................... 49
2.5.2 Tert-butyl (2(methylsulfonamido)ethyl)carbamate ........................... 50
2.5.3 Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)aceta
te, Boc-Linker(OMe)................................................... 51
2.5.4 Linker(OMe)-Lys(Boc)-NHCbz, Dimer ................... 52
ii

2.5.5 Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer ............ 54
2.5.6 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz,
Tetramer .................................................................. 56
2.5.7 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-LeuNHCbz, Pentamer ...................................................... 58
2.5.8 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-LeuLys(Boc)-NHCbz, cHYD1 Non-Recognition Strand
(cHYD1 NRS) ............................................................ 59
2.6 References .................................................................. 61

CHAPTER THREE: DEVELOPMENT OF A NOVEL hGH ANTAGONIST
AND AGONIST ................................................................... 63
3.1 Introduction................................................................. 63
3.2 Specific Aim ................................................................. 68
3.3 Synthesis .................................................................... 84
3.4 Chemical Evaluation ..................................................... 85
3.5 Biological Evaluation ..................................................... 86
3.6 Optimization ................................................................ 87
3.6.1 Peptide Docking Procedure Overview ................... 88
3.6.2 Linker Optimization ........................................... 91
3.6.2.1 Linker Docking Procedure Overview .......... 92
3.6.3 APA Example .................................................... 95
3.6.4 APA Synthesis and Linkage ............................... 100
3.6.4.1 Lysine Derivative Synthesis ................... 101
3.6.4.2 Coupling ............................................. 102
3.7 Future Considerations ................................................. 102
3.8 Experimental Procedures ............................................. 103
3.8.1 Antagonist Synthesis ....................................... 103
iii

3.8.2 Agonist Synthesis ............................................ 105
3.8.2.1 5-Aminoisophthalic Acid ........................ 105
3.8.2.2 5-((tertbutoxycarbonyl)amino)isophthalic acid............... 106
3.8.2.3 Fmoc-Lys(Boc)-OAllyl ........................... 107
3.8.2.4 hGH Linker .......................................... 108
3.8.2.5 Agonist ............................................... 109
3.9 References ................................................................ 111

APPENDIX A: SELECTED 1H AND

13

C NMR SPECTRA .............................. 114

APPENDIX B: SELECTED MASS SPECTRA ............................................. 124

APPENDIX C: LIST OF ABBREVIATIONS ............................................... 135

ABOUT THE AUTHOR ..................................................................End Page

iv

LIST OF TABLES
Table 2.1 Coupling Agent Comparisons

35

Table 3.1 Peptide-Only Conformational Energies

93

Table 3.2 Full Complex Minimization Energies

94

Table 3.3 “Major” Receptor Hydrogen Bonding

98

Table 3.4 “Minor” Receptor Hydrogen Bonding

99

v

LIST OF FIGURES
Figure 1.1 Peptide Bond Formation

3

Figure 1.2 Resonance structure of a peptide bond

4

Figure 1.3 Alpha Helix

6

Figure 1.4 Parallel Beta Sheet

7

Figure 1.5 Anti-Parallel Beta Sheet

8

Figure 1.6 Beta Turn

9

Figure 1.7 Beta Hairpin

10

Figure 1.8 L-Asn-Gly Turn Promoter

11

Figure 1.9 Gellman Peptide, D-Pro-Gly Turn Promoter

12

Figure 1.10 Robinson Cyclic Peptide, D-Pro-L-Pro Turn
Promoter

14

Figure 1.11 McLaughlin β-turn Promoter

14

Figure 1.12 Unprotected Amino Acid Synthesis

18

Figure 1.13 Common Carboxyl Protecting Groups

20

Figure 1.14 Common Amino Protecting Groups

21

Figure 1.15 DCC Activation

23

Figure 1.16 Peptide Bond Formation After Activation

24

vi

Figure 1.17 Common Coupling Agents

26

Figure 2.1 cHYD1 Structure

32

Figure 2.2 cHYD1 via Molecular Modeling

33

Figure 2.3

®

T3P Mechanism

36

Figure 2.4 Compound 2.5.1

49

Figure 2.5 Compound 2.5.2

50

Figure 2.6 Compound 2.5.3, Boc-Linker(OMe)

51

Figure 2.7 Compound 2.5.4, Dimer

52

Figure 2.8 Compound 2.5.5, Trimer

54

Figure 2.9 Compound 2.5.6, Tetramer

56

Figure 2.10 Compound 2.5.7, Pentamer

58

Figure 2.11 Compound 2.5.8, cHYD1 Non-Recognition
Strand (cHYD1 NRS)

59

Figure 3.1 PDB of 1HGU

64

Figure 3.2 PDB of hGHR 1, hGHR 2, and hGH

67

Figure 3.3 PDB of 1:1 hGH:hGHR

69

Figure 3.4 R64 of hGH showing alkyl-aromatic stacking
with W169 of hGHR

71

Figure 3.5 K172 of hGH showing alkyl-aromatic stacking
with W104 of hGHR

72

vii

Figure 3.6 γ-CH 3 of T175 of hGH in the same plane as
W104 of hGHR

73

Figure 3.7 Cyclized peptidic scaffold originally used to
mimic hGH functional epitope

74

Figure 3.8 Surface area showing “hump” around the
“hot spot”, W104 and W169

75

Figure 3.9 Proposed cyclized peptide molecule bound to
hGHR

77

Figure 3.10 K8 showing alkyl-aromatic stacking with
W104 of hGHR

79

Figure 3.11 K5 showing alkyl-aromatic stacking with
W169 of hGHR

80

Figure 3.12 Hydrogen bonding shown between proposed
cyclized peptide molecule and hGHR

81

Figure 3.13 Comparison of hGHR binding between hormone
and dimerized antagonists
Figure 3.14 Proposed peptidic molecule including linker

viii

82
83

Figure 3.15 Rendering of proposed molecule dimerizing
hGHR

84

Figure 3.16 New peptidic scaffold introducing 6-atom
turn promoter

87

Figure 3.17 Peptide not binding to receptor during
minimization

89

Figure 3.18 Peptide binding to receptor after minimization

90

Figure 3.19 One polyethylene glycol unit, PEG

91

Figure 3.20 5-aminoisophthalic acid, APA

92

Figure 3.21 Two polyethylene glycol units, PEG2

92

Figure 3.22 Overlay of di-cyclic peptides

94

Figure 3.23 Overlay of all with PDB 3HHR

95

Figure 3.24 “Side view” of di-cyclized peptide with APA
linker

96

Figure 3.25 “Overhead view” of di-cyclized peptide with
APA linker

97

Figure 3.26 Compound 3.8.2.1, APA

105

Figure 3.27 Compound 3.8.2.2

106

Figure 3.28 Compound 3.8.2.3, Fmoc-Lys(Boc)-OAllyl

107

Figure 3.29 Compound 3.8.2.4, hGH Linker

108

ix

LIST OF SCHEMES
Scheme 1.1 Solid Phase Peptide Synthesis

16

Scheme 2.1 Synthesis Scheme for cHYD1 Non-Recognition
Strand

34

Scheme 2.2 Linker Purification Scheme

38

Scheme 3.1 Schematic of hGH Dimerization

66

Scheme 3.2 Schematic of APA Synthesis and Linkage

100

Scheme 3.3 Fmoc-Lys-OAllyl Synthesis

101

x

Philip Murray
ABSTRACT
Inhibiting protein-protein interactions to achieve a therapeutically
desired effect has been a goal in the field of drug discovery for
decades. Recently, advances in peptidomimetics have led researches
to the use of cyclized peptides to achieve this goal. Cyclization of
linear peptides restricts the number of conformations of the peptide,
increasing the peptide’s affinity to binding to the desired target.
Cyclization also stabilizes the peptide, allowing the peptide to be
resistant to proteases. This study explores the optimization of solution
phase synthesis of an important integrin-mediated cell adhesion cyclic
peptide for the therapeutic inhibition of multiple myeloma, cHYD1.
cHYD1 was originally synthesized via solid phase peptide synthesis,
and the need for a scaled up synthesis version was needed after
positive bioactivity results were obtained. Chapter 3 includes the
molecular modeling exploration of a possible new mechanism to which
cyclized peptides could work, in which, rather than a recognition and
non-recognition strand being implemented, a specific directional face is
used for protein-protein interaction. This was done with the
xi

implementation of an antagonistic cyclic peptide to replace human
growth hormone in its interaction with the human growth hormone
receptor, and the subsequent di-cyclic peptide agonist.

xii

CHAPTER ONE:
INTRODUCTION

1.1 Peptide and protein overview
Proteins are biological macromolecules composed of one or more
polypeptides folded in a globular fashion that facilitates a biological
function. These polypeptides are made up of linear chains of amino
acids. A peptide is a linear chain of two or more amino acids, linked
via amide bonds. A chain of 2 to 100 amino acids and carrying a
molecular weight of less than 10 kDa is usually defined as a peptide,
while longer chains reflect polypeptides, those with defined structure
and function being referred to as proteins.
There are 20 naturally occurring amino acids, with countless
other synthetic mimics and analogs. Each amino acid contains an αcarbon, to which a carboxyl group, an amino group, and a variable
side chain which defines the given amino acid are attached. The
combination of the variable side chains in a peptide and/or protein
structure inevitably give rise to the conformation and biological activity
of the specific analog. Amino acids link together via an amide bond,
1

specifically being referred to as a peptide bond. In laboratory
synthesis, the carboxylate end of a given amino acid must be
“activated” via a coupling agent. The amine group of the second
amino acid then creates a nucleophilic attack on the carbonyl of the
first amino acid, producing a peptide bond while releasing a molecule
of water. The free carboxyl end of the peptide is known as the Cterminus, while the free amino end of the peptide is known as the Nterminus (Fig 1.1). Amino acids within a peptide are referred to as a
“residue”.

2

Fig 1.1 Peptide Bond Formation

The peptide bond has some double bond characteristics due to
resonance, inhibiting free rotation around the bond (1), leaving the
backbone α-carbons in a coplanar state. The other dihedral angles
determine the shape of the particular peptide.

3

Fig 1.2 Resonance structure of a peptide bond

The primary structure of a protein is that of a linear peptide.
When folded among other peptides, secondary structures such as αhelices, β-sheets, and β-turns are produced. These secondary
structures come about via geometrical bond angles between amino
acid residues and hydrogen bonds between adjacent amino acid
residues, stabilizing the structure. When these secondary structures
interact and fold among themselves, the tertiary structure of the
protein is born, giving rise to its three-dimensional shape, leading to
the protein’s basic biological function. This is held together by
hydrogen bonds, disulfide bonds, and sometimes salt bridges. The
quaternary structure of a protein is the intermolecular interaction of
two or more tertiary structures, leading to a protein complex which
works in unison for a given biological activity.

4

1.2 Secondary Structures
The predominant secondary structures of proteins are α-helices,
β-sheets, and β-turns. The right-handed α-helix structure makes up
roughly 31% of all protein structures, while β-sheets make up 28%
and β-turns make up 25%, respectively (2). These structures allow
opportunities for drug design to mimic such folding, providing a
synthetic recognition surface capable of simulating protein-protein
interactions, further accentuating or inhibiting downfield chemical
responses associated with the given protein’s biological activity.
The α-helix (Fig 1.3) is a coil usually formed in a right-handed
conformation. Each main-chain nitrogen of a peptide donates a
hydrogen to the oxygen of the main-chain carbonyl exactly four
residues downfield, forming a hydrogen bond. Each residue allows for
a 100° turn. There are 3.6 residues per turn at a translation of 1.5 Å
along the axis, giving an overall vertical distance of 5.4 Å per turn.
Methionine, alanine, leucine, uncharged glutamine, and lysine have the
highest propensity to helical formation, while glycine and proline have
the lowest. Glycine seems to be too flexible in allowing a helical
conformation to occur, while proline is too rigid and does not the
propensity to form a main-chain hydrogen bond (3). Alpha-helices are
involved in DNA binding, cell-membrane crossing, and some
mechanical properties.
5

Fig 1.3 Alpha Helix

β-sheets are important secondary structures for protein-protein
and protein-DNA interactions, creating desired and undesired biological
functions. β-sheets comprise of two or more β-strands, running either
parallel (Fig 1.4) or anti-parallel (Fig 1.5) to each other. The direction
is determined from N- to C-terminus. Hydrogen bonding between the
α-nitrogen of one strand and the nearer carbonyl of the other adjacent
strand produces the stability and conformation of the sheet. Antiparallel β-sheets have shorter, more stable hydrogen bonds than their
parallel counterparts. Both parallel and anti-parallel β-sheets have
adjacent side-chain residues which point in opposite directions, leaving

6

an extended conformation. This allows for recognition at both the top
and bottom faces of the sheet. Parallel β-sheets are usually found in
the hydrophobic core of proteins, whereas anti-parallel β-sheets
usually display amphipathic characteristics and can be found at the
surface of proteins. Amino acids with high β-sheet propensity include
tyrosine, phenylalanine, tryptophan, threonine, valine, and isoleucine.

Fig 1.4 Parallel Beta Sheet. Hydrogen bonds are depicted by dotted lines. Arrows
point from N- to C-terminus.

7

Fig 1.5 Anti-parallel Beta Sheet. Hydrogen bonds are depicted by dotted lines.
Arrows point from N- to C-terminus.

The β-turn (Fig 1.6) is an extremely important biological
structure, as it allows for a peptide to complete a 180° turn, allowing
for ease in folding, creating a globular shape, and providing synthetic
access for protein-protein recognition (4-6). They consist of loops of
four residues, involving a hydrogen bond between the ith and ith+3
residues, stabilizing the turn.

8

Fig 1.6 Beta Turn

The β-turn has led to the discovery of the β-hairpin (Fig 1.7),
and in turn β-hairpin mimics, which have a wide variety of functional
use in drug discovery. The β-hairpin is the simplest form of two βsheets formed together in an anti-parallel arrangement linked by a
short loop of two to five residues which form a loop or turn. They vary
widely in their formation, occurring in isolation or as a series of
hydrogen bonds (7).
9

Fig 1.7 Beta Hairpin

1.3 Peptidomimetics
Peptidomimetics is the strategy of synthetically imitating a
peptide via some sort of molecular modification in an attempt to
advantageously alter the molecular properties of the peptide. This is
done in a non-natural environment, such as integrating non-natural
amino acids or the alteration of the normal peptide backbone. This
process has a significant role in drug discovery.
D-peptides, derived from the sequencing of D-amino acids, have
long been a tool of peptidomimetics. D-amino acids rarely occur
naturally in comparison to their L-amino acid counterparts. Their sidechains are the mirror image of the L-amino acid versions. They are
not easily digested or degraded, and can have a low immunogenic
response, allowing for an attractive drug model (8).

10

More importantly, peptidomimetics has recently headed towards
the mimicking of β-hairpins as a way to increase protein-protein
interaction and increase biological activity with drug-based peptides.
The approach is to replace a hairpin loop of a known structure with a
template that stabilizes the β-hairpin. This template is known as the
β-turn promoter, and facilitates a cyclic β-sheet conformation. These
turn promoters have been varied greatly, using both natural and nonnatural amino acids. Originally, Blanco, et al, found that the L-Asn-Gly
dipeptide was an efficient β-turn promoter (Fig 1.8) (9). This was later
surpassed by Gellman’s group, using D-Pro-Gly as the template,
signifying the use of D-amino acids as an increased model for β-hairpin
conformation (Fig 1.9) (10). Since these discoveries, a myriad of
different groups have reported a vast array of β-turn promoters,
ranging from simple dipeptides to complex non-natural amino acid
derivatives (11-13).

Fig 1.8 L-Asn-Gly turn promoter

11

Fig 1.9 Gellman peptide, D-Pro-Gly turn promoter

1.3.1 Cyclic Peptidomimetics
Linear peptides are poor synthetic drugs, as they are too
conformationally flexible, existing as random structures in solution.
This leads to low bioavailability, and they are easily degraded by
proteases in the body. This can be combatted by restricting the
flexibility of the molecule via cyclization, making the structure
extremely rigid. Molecules designed in a prearranged conformation
and owning a fixed shape are better recognized by their targets due to
the lower amount of entropy loss associated with binding, leading to a
higher affinity for the target and, theoretically, higher desired
biological activity. Cyclic peptides also cannot be recognized by
proteases, allowing for a longer lifespan for the drug.
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In using β-hairpin mimicking schemes, a peptide can be
completely cyclized using a β-turn promoter on both ends of the
cyclized product. The core residues are placed on the recognition
strand, while the non-recognition strand can be used to optimize
bioavailability and bioactivity.
Kopple, et al, originally used a D-Pro-L-Pro template to
accomplish cyclization, proving β-sheet structures can be attained with
such a β-turn promoter (14). Robinson, et al, used this template
extensively, including forming a cyclic peptide that inhibits p53/MDM2
interaction (Fig 1.10) (15). This template is discussed further in
Chapter 3 as a way to develop and model a particular cycle peptide.
McLaughlin, et al, developed a non-natural amino acid derivative,
methylsulfonamido aminoethyl glycine (Fig 1.11) (unpublished
results), as another stable β-turn promoter which is used later in
Chapters 2 and 3, as well.

13

Fig 1.10 Robinson Cyclic Peptide, D-Pro-L-Pro turn promoter

Fig 1.11 McLaughlin β-turn promoter
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1.4 Solid Phase and Solution Phase Peptide Synthesis
Solid Phase Peptide Synthesis (SPPS) was originally designed by
Robert Merrifield in 1959, authoring a paper in 1963 describing his
work (16). The principle behind SPPS is the binding of the peptide to
an immobilized solid support system, usually a polymeric resin bead.
After reaction of each adjacent amino acid in a step-wise fashion,
unreacted reagents are easily washed away with solvent before
proceeding to the next step. Eventually, the peptide is cleaved from
the resin, leaving just the desired product. Scheme 1.1 represents
SPPS, including amino acid deprotection and activation.

15

Scheme 1.1 Solid Phase Peptide Synthesis Scheme

SPPS is advantageous in that it uses an immobilization scheme
throughout the synthesis. This allows for easy isolation of the
16

compound and its intermediates through synthesis. Bead
manipulation can be performed depending on the sequence desired.
SPPS is easily automated, and reactions are relatively clean, as little to
no purification is needed. However, disadvantages of SPPS include
poor reaction monitoring, the necessary need for sometimes complex
correct linkers between the resin and the desired product, and the fact
that excess reagents are used, causing an extremely wasteful and
costly environment.
In comparison, solution phase peptide synthesis includes an easy
understanding of reaction development, as peptide synthesis has been
known for decades. There is no need for excess reagents, as all
reagents can be used on an equivalent scale. Reaction monitoring is
also relatively easy. Most importantly, solution phase synthesis can be
scaled up to large quantities while incurring very little in cost.
Automation does take some creativity, and purification steps are
needed, but both can be limited with enough resources. Chapter 2
explains in full detail the scaling up of a peptide originally synthesized
via SPPS.

17

1.5 Protecting Groups
With peptide synthesis, the use of protecting groups is essential
to the desire to create clean product with no unnecessary side
products. The primary amine of the main-chain of an amino acid, as
well as primary amines on any given side-chains, is very reactive with
any free carboxyl group available, especially after carbonyl activation.
If protecting schemes were not employed, a myriad of different
reactions would occur involving both unprotected ends of the amino
acid (Fig 1.12).

Fig 1.12 Unprotected Amino Acid Synthesis

Protecting groups are employed to curb such reactions, inhibiting
the nucleophilic attack needed to form a peptide bond due to steric
hindrance. These are bulky groups placed on the free amino and free
18

carboxyl groups that can be removed via different mechanisms, such
as the addition of acid, base, or by hydrogenolysis. They are defined
by their deprotection or removal schemes, such as being “acid labile”
for acid removal and “base labile” for base removal. Some protecting
groups are removed via hydrogenolysis, the process of hydrogen being
used to cleave carbon-carbon or carbon-heteroatom bonds (17). For
our work later, it will be shown that we use a palladium catalyst on
carbon along with a hydrogen source to elicit the deprotection.
For solution phase synthesis, carboxyl protecting groups
primarily include methyl esters (strong acid or base labile), tert-butyl
esters (acid labile), benzyl esters (removed by hydrogenolysis), and
allyl esters (removed via palladium catalyst). Other lesser used
carboxyl protecting groups include silyl esters (acid or base labile) and
oxazolines (strong acid labile).

19

Fig 1.13 Common Carboxyl Protecting Groups

Amino protecting groups consist primarily of 9fluorenylmethyloxylcarbonyl (Fmoc, base labile), tert-butyloxycarbonyl
(Boc, acid labile), and carboxybenzyl (Cbz, removed by
hydrogenolysis). Other protecting groups include tosyl, benzyl, and
acyl groups.

20

Fig 1.14 Common Amino Protecting Groups

1.5.1 Orthogonal Protection Schemes
The orthogonal protection scheme was first introduced by Robert
Merrifield in 1977 (18). This scheme allowed for different protecting
groups to be deprotected selectively, leaving only one local area open
for attack within a given peptide bond formation. If a C-terminal
carboxyl group is protected via a base labile protecting group, then the
amino acid or corresponding peptide’s N-terminal amine would be
protected with either an acid labile group or a group readily removed

21

by hydrogenolysis. If a side-chain or side-chains necessitating a
protecting group were present, then all side-chains would be protected
with similar labile protecting groups, and not carrying the same
labiality as either the N- or C-terminus. Later, we explore a situation
in which ultimately the orthogonal protection scheme needed for our
cHYD1 peptide gives rise to a C-terminal methyl ester protecting group
(base labile), an N-terminal Cbz protecting group (removed via
hydrogenolysis), and side-chain amines consisting of Boc protecting
groups (acid labile). Since Merrifield, numerous studies have
developed similar and more complex orthogonal protection schemes
(19).

1.6 Coupling Agents
Without any help, formation of the peptide bond between the
amino group of one amino acid and the carboxylic group of another
amino acid is energetically unfavorable. In nature, this is overcome by
enzymes that catalyze the reaction. The enzymes “activate” the
carboxyl group, making the carbonyl carbon a better electrophile,
allowing for the free amine of the other amino acid to perform a
nucleophilic attack. This can be mimicked in synthesis via coupling
agents. The hydroxyl group is replaced by an electron withdrawing
22

substituent, enhancing the electrophilicity of the carbonyl. Fig 1.15
shows the mechanism of activation with N,N’-dicyclohexylcarbodiimide
(DCC). After activation, the group is a very strong electron
withdrawing group, allowing for nucleophilic attack by the free amine
of the incoming amino acid (Fig 1.16).

Fig 1.15 DCC activation
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Fig 1.16 Peptide Bond Formation After Activation

There are generally two types of activating agents used in
peptide synthesis: carbodiimides and triazoles. Carbodiimides were
first developed for this use, the most notable version being DCC
referenced above and the original activating agent used in the solution
phase synthesis of cHYD1 mentioned in Chapter 2. Carbodiimides,
while useful, yield insoluble urea which must be eliminated through
purification. They are also too reactive, sometimes causing
racemization of the amino acid. To combat this, triazoles such as 1hydroxybenzotriazole (HOBT) were developed. They are less reactive,
giving less danger to racemization. Since the development of
triazoles, newer activating agents have evolved, eliminating the use of

24

carbodiimides completely. They include the use of uronium and
phosphonium salts to help with activation. One such activating agent,
HCTU, is now used regularly for SPPS in our lab with a high degree of
success. Fig 1.17 shows the common coupling agents used in current
peptide synthesis procedures.

25

Fig 1.17 Common Coupling Agents (courtesy Dr. Priyesh Jain)
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CHAPTER TWO:
cHYD1 SOLUTION PHASE SYNTHESIS OPTIMIZATION

2.1 Introduction
Multiple Myeloma (MM) is an incurable hematopoietic malignancy
due to the lack of elimination of minimal residual disease (MRD) and
the strong multi-drug resistance (MDR) emergence of tumor cells
following standard chemotherapeutic treatments (1). MRD is found in
the bone marrow compartment, indicating that the bone marrow
environment allows for chemical signaling that includes the failure to
eliminate MRD, leading to re-emergence of the disease (2).
Hazlehurst, et al, have shown that adhesion of hematopoietic cells
such as MM tumor cells to fibronectin (FN) in the extracellular matrix
stimulates tumor cell survival and prompts chemotherapeutic drug
resistance, referred to as cell adhesion mediated drug resistance,
CAM-DR (3-9). The disruption of the tumor-stromal cell adhesion has
since been the focus of a variety of research groups to increase the
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efficiency of standard chemotherapeutic treatments as a way of
eliminating MRD and avoiding MDR.
Using combinatorial peptide libraries and a functional binding
assay, Cress, et al, identified several peptides that inhibited β1
integrin mediated cell adhesion of prostate cancer cells to fibronectin,
laminin, and collagen IV (10). Ultimately, the lead peptide derived
from these studies was determined to be the all D-amino acid peptide
referred to as HYD1 (kikmviswkg), which prevents integrin binding
epithelial prostate carcinoma cells with extracellular matrices (11, 12).
The inhibition of cell adhesion was attributed to dissociation of
adhesion and resulting signaling events downstream rather than by
cell death (9, 13, 14). Hazlehurst, et al, have shown that HYD1 blocks
α4β1 integrin mediated adhesion of MM cells to fibronectin, increasing
the efficiency of standard chemotherapeutic treatments against MM
(15). The same study has shown that HYD1 works similar to RGD
(Arg-Gly-Asp) motif peptides, which block integrin ligand interactions.
However, unlike RGD peptides, which induce apoptic cell death
independent of the presence of the ligand via activation of caspases,
release of apoptosis-inducing factor, and induction of double stranded
DNA breaks signifying endonuclease activation (16), HYD1 causes
necrosis via the loss of the mitochondrial membrane potential, loss of
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total cellular ATP, and an increase in reactive oxygen species (ROS)
production. This happens as a single event in vitro and in vivo (15).
Hazlehurst, et al, performed truncated N- and C-terminus
studies on D-HYD1, leading to the discovery of the MVISW region as
the likely core region for biological activity. Further studies showed
that replacing I with V further improved biological activity of the DHYD1 analog. The strategy of cyclizing linear peptides as a means to
limit the number of conformations available is a well-known strategy
that increases the affinity of the binding of the peptide to the target,
allowing for a beta-hairpin turn that further constrains the peptide into
a beta-sheet conformation. This also allows for the amide bonds to
not be recognized by proteases, allowing for an extremely stable
compound. The cyclization of D-HYD1 (cD-HYD1) allowed the MVVSW
recognition strand region to be in this beta-sheet-like conformation,
and produced a 2-fold increase in activity over the linear D-HYD1. The
non-recognition strand was determined to be KLKLK, in theory to help
with the amphipathicity of the overall compound. The corresponding
cyclic version of L-HYD1 actually increased biological activity another
2-fold. Structure-Activity Relationship (SAR) studies showed that
replacing S with A and M with nor-Leucine further improved biological
activity. Various turn promoters, to help with cyclization and further
stabilize the beta-sheet conformation, were explored, eventually
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settling on a methylsulfonamido aminoethyl glycine derivative on one
side and a d-Prolinol derivative on the other. All of these studies
eventually gave rise to cHYD1 (Fig 2.1 and 2.2), with an IC 50 of 1.2
µM, as compared to the lead D-HYD1 IC 50 of 31.8 µM.

Fig 2.1 cHYD1 Structure
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Fig 2.2 cHYD1 via molecular modeling

2.1.1 Solution Phase Synthesis Strategy
It was determined that the best route for overall synthesis of
cHYD1 via solution phase was to synthesize it fragmentally. The idea
would be to synthesize the non-recognition strand with one turn
promoter (referred to as “linker”) separate from the recognition strand
with another turn promoter (“linker”). The two subsequent hexamers
would then be coupled together at one end first, creating the linear
12-mer, which would then be cyclized, resulting in the final cHYD1
product. This route of synthesizing fragments was thought to be most
beneficial, as it would minimize any loss that could occur with further
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additional couplings, as well as minimize aggregation of the growing
peptide, theoretically allowing for better overall yields with each step.
The following scheme (Scheme 2.1) and report are strictly from the
non-recognition strand synthesis development, as Hyun Joo Kil was
respectively placed on recognition strand synthesis development.

Scheme 2.1 Synthesis Scheme for cHYD1 Non-recognition strand

34

2.1.2 Coupling Agents
While DCC/HOBT is the preferred coupling agent system for most
solution phase peptide synthesis schemes, a newer reagent,
made its way to the market.

®

T3P has

®

T3P has its advantages in that

purification is easy, subsequent yield is high, epimerization and
toxicity are low, and it is relatively inexpensive.
Table 2.1 Coupling Agent Comparisons (17)

®

T3P actually has three active sites, activating the carboxyl

group of the amino acid, and producing a water-soluble side-product
which is easy to remove (Fig 2.3).
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Fig 2.3 ®T3P Mechanism (17)

2.2 Linker Development
2.2.1 Tert-butyl-2-aminoethylcarbamate
The linker was derived initially from its obvious root,
ethylenediamine. In order to ensure proper alkylation to only one of
the free amines, the other side must first be protected, preferably via
a Boc group for a viable orthogonal scheme. This was done through
the introduction of di-tert-butyl dicarbonate. Extremely dilute
conditions were needed so as to only produce the mono-protected
substituent. It was found that the use of nine equivalents of
ethylenediamine to di-tert-butyl dicarbonate with a relatively large
amount of protic solvent (in this case, tetrahydrofuran, THF) at 0°C
was sufficient. These dilute conditions combined with the cold
temperature allowed for the reaction rate to be slowed down enough
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to allow for only mono-protected substituent to be produced. Any
smaller ratio resulted in some unwanted di-protected substituent, and
any larger ratio would just result in more excess waste. Purification of
the final mono-protected product was unnecessary, as a simple water
workup and concentration was sufficient in removing any excess
ethylenediamine.

2.2.2 Tert-butyl (2-(methylsulfonamido)ethyl)carbamate
Originally, the next step was to develop methyl 2-((2-((tertbutoxycarbonyl)amino)ethyl)amino)acetate, involving the N-alkylation
of tert-butyl-2-aminoethylcarbamate via the use of methyl
bromoacetate. While the reaction was simple and efficient, albeit
somewhat lengthy in time, purification via chromatography was
necessary. This would prove costly financially, time-wise, and in yield.
To avoid this problem, a different route was explored successfully.
Rather than first N-alkylating then adding the methylsulfonyl group to
attain the linker, the order was reversed. Methanesulfonyl chloride
was added in a 1:1 ratio to tert-butyl-2-aminoethylcarbamate in the
presence of triethylamine (TEA) for one hour. After water workup and
concentration, the product was found to be an off-white solid at a
90.8% yield and with only one TLC spot and a clean LCMS profile. This
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step essentially increased yield, shortened the overall reaction time
(24 hours to 1 hour), and eliminated the need for a costly
chromatography purification.

Scheme 2.2 Linker Purification Scheme

2.2.3 Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)acetate, BocLinker(OMe)
The final step in the development of the linker was to N-alkylate
the secondary amine with the methanesulfonyl group attached to it.
First, the proton needed to be pulled off. This was done via sodium
hydride. Once this was done, methyl bromoacetate was introduced in
a 1:1 ratio to the starting material. After water was used to quench
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any remaining sodium hydride an hour into the reaction, a water
workup and concentration revealed a crude solid product.
Recrystallization of the pure product was realized through a 1:1 ethyl
acetate:hexane mixture, revealing a white solid with a pure TLC and
LCMS profile. Thus concluded the development of the linker without
the need for any costly purification steps and done in a quick and easy
manner.

2.2.4 Linker Deprotection
As with most deprotections of Boc groups in peptide chemistry,
trifluoroacetic acid was first used to deprotect the linker to allow for
the free amine to be ready for amino acid coupling. Unfortunately,
removing excess trifluoroacetic acid via a normal water workup was
not possible. The deprotected linker is hydrophilic given the nature of
its free amine and methylsulfonyl group and goes into the water layer
in any organic/water extraction process. Attempting to remove excess
trifluoroacetic acid via rotovap seemed ideal given its relatively low
boiling point (72.4 °C), however, trace amounts were still left behind
without regard to the amount of excess trifluoroacetic acid used. Even
using excess DIEA in an attempt to neutralize the solution did not
completely remove it. This ultimately contributed to the lower yields
39

in the dimer synthesis step, as the carboxylate of trifluoroacetic acid
would be activated via the coupling agent, essentially capping a
somewhat significant portion of linker.
Very recently, our group has discovered the use of
methanesulfonic acid as a viable alternative to trifluoroacetic acid as a
means to deprotect the Boc group from the linker. Methanesulfonic
acid deprotection yields an inert side product that does not interfere
with coupling, and can be easily neutralized via DIEA. Four
equivalents of methanesulfonic acid are needed, which results in a
deprotection time of less than ten minutes. DIEA would then be used
at a slight excess to neutralize the remaining solution so as not to
allow for further side-chain Boc group deprotection of the following
amino acid coupling (in this instance, Z-Lysine(Boc)-OH), followed
immediately by the next coupling step. This procedure decreases
overall time needed for synthesis, as the painstaking task of
attempting to remove excess trifluoroacetic acid is eliminated, saving
up to a couple days in time overall. Preliminary data also shows that
the subsequent overall dimer yield is increased.
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2.3 Amino Acid coupling
The original idea for the amino acid coupling steps would be to
simply use DCC/HOBT as the coupling agents, a well-regarded process
in solution-phase peptide synthesis. While this process works for our
synthesis, purification is problematic, as there is a need to remove the
unwanted urea derivative, and usually involves costly column
chromatography. Other coupling agents were explored in an attempt
to avoid such purification, eventually leading to the use of

®

T3P.

®

T3P

provides a clean and efficient coupling, and can be easily removed
through a water extraction.
The other consideration for synthesis was the orthogonal
protection scheme needed for the subsequent amino acids. Given that
the linker was protected on the C-terminal end with a methyl ester, a
base labile protecting group, the main-chain amines as well as the
side-chain amine of each lysine group could not be of the same nature.
Therefore, Fmoc was immediately eliminated from consideration. The
first idea was to mimic the linker protection scheme, using the Boc
group to protect the main-chain amines. This would mean the sidechain amine of each lysine would need to be protected by a group that
was not either base or acid labile, leading to the use of the
carboxybenzyl (Cbz) protecting group. Unfortunately, this led to a
dimer product that was oily in nature, causing purification problems,
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including the use of column chromatography, and resulting in low
yields. However, when the protecting groups were switched, allowing
for a Cbz protected main-chain amine along with a Boc protected sidechain amine of lysine, the product was found to be solid in nature,
allowing for easy, non-column aided purification, resulting in a drastic
cut in overall synthesis costs financially and time-wise. It also meant
that trifluoroacetic acid would not be needed for any subsequent
deprotections during the entire synthesis scheme, as simple
hydrogenation was the method used to remove the Cbz group from
each main-chain amine prior to coupling.

2.3.1 Dimer Synthesis
After linker deprotection, the first amino acid in the sequence,
lysine, was introduced. This was done via commercially available ZLysine(Boc)-OH. After trifluoroacetic acid deprotection of the linker,
the free amine compound was dissolved in DCM and treated with 2.5
equivalents of DIEA. While on a small scale this was not too difficult,
at a larger, 2 gram scale, the compound proved difficult to dissolve.
The trifluoracetic acid salt seemed to be the culprit, as 40mL of DCM
was needed for complete solvation, which still was not fully realized
until the introduction of the DIEA. Once the compound was in
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solution, 1.0 equivalent of Z-Lysine(Boc)-OH was added, the solution
was cooled to 0°C, and T3P® was added. The company that
produces

®

T3P, Archimica, recommends using 1.2 equivalents of

®

T3P

per coupling. Our results show that increasing this to 2.0 equivalents
seemed to be most ideal, especially as the scale of the reaction was
increased. Anything beyond 2.0 equivalents of

®

T3P seemed to cause

purification issues, possibly due to the cagey, oily nature of the
reagent. The reaction was under dry conditions at all times, as water
cannot be present due to possible peptide bond hydrolysis as well
as

®

T3P quenching. While the reaction seemed to near completion via

TLC (100% ethyl acetate) in an hour, it was allowed to run overnight
to maximize coupling time. After the reaction was observed to be
done via TLC, water was used to quench any remaining

®

T3P.

The

resulting solution was concentrated, and then dissolved in ethyl
acetate. At larger scales, some crude product precipitated under
100% ethyl acetate conditions. This precipitate was filtered off, and
the filtrate was extracted three times with water. This removed the
majority of the excess

®

T3P, its side product derivatives, and any

unreacted free amine linker. The organic layer was concentrated, and
the crude solid product was added to the previous precipitate.
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2.3.1.1 Dimer Purification
Given that the crude product was solid in nature,
recrystallization was the preferred method of purification. Several
different ratios of ethyl acetate:hexanes were attempted without much
success. Finally, the use of 100% di-ethyl ether afforded the desired
pure product, precipitated as a white solid in roughly an hour. The
ether layer consisted of any remaining

®

T3P and side products, as well

as any unreacted Z-Lysine(Boc)-OH, making it the perfect purification
solvent. This made for a cheap, easy, and quick purification scheme.

2.3.1.2 Dimer Yield
The yield for the dimer at the larger scale was maximized at
54.6% through the above conditions. As mentioned earlier,
trifluoroacetic acid played a role in limiting the synthesis of the dimer,
through its carboxylate activation via

®

T3P. Preliminary data shows

this problem to be alleviated using methanesulfonic acid as the
deprotection mechanism.
Another cause for low yield is the free amine linker itself. Given
that it is a six atom compound, it seems that a certain percentage is
self-cyclizing, creating a six-member ring that is extremely stable.
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This compound is found in the ether layer during the purification step,
therefore there’s no carry over to the following coupling steps.

2.3.2 Cbz Deprotection
Before the coupling of the trimer and subsequent amino acids,
the Cbz group of the main-chain amine must be removed. This is
done via hydrogenation along with a palladium catalyst. The
procedure used involved methanol as the solvent, with 10% palladium
on carbon powder as the catalyst. Hydrogen is then pumped into the
reaction vessel at 55psi, and the mixture is allowed to stir overnight,
giving way to the free amine. At the 2 gram scale, 100mL of methanol
is needed to dissolve the protected compound. The reaction is filtered
through celite, the filtrate is concentrated, and the resulting free
amine is found at quantitative yields.
There have been some attempts to find alternative hydrogen
sources rather than pressurized hydrogen, as the idea to scale up to
much larger industrial levels will leave the current procedure to
become unrealistic. Ammonium formate was first used, as the
compound decomposes into ammonia, carbon dioxide, and hydrogen
gas when placed in methanol. This would conceivably be an easy
reagent to remove in excess, however, that was not found to be the
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case, as ammonium formate would be found post-reaction in every
instance regardless of time spent in reaction and under vacuum.
Formic acid was also used, as it decomposes into carbon dioxide
and hydrogen gas when placed in methanol, and is a liquid at room
temperature, allowing for easier measuring and transferring methods.
While the reaction happened almost instantaneously, resulting in full
Cbz deprotection in a matter of seconds, the main problem seemed to
be the removal of all excess formate salt. The formate acted in the
same manner as the trifluoroacetate in the Boc deprotection, being
activated via

®

T3P in the next coupling step, and interfering with

coupling and subsequent yield. This side product was also practically
impossible to separate from the pure products. In both the
ammonium formate and formic acid deprotection schemes, a water
workup could not be performed because the free amine compound is
too hydrophilic and goes into the water layer.
Very recently, triethylsilane was used as a hydrogen source. A
minimal amount of methanol was used to dissolve the dimer, 400mg
of Pd(10%)/C was added, and 4 equivalents of triethylsilane was
added. The reaction went to completion in under one minute. The
side product is inert, and is easily removed via rotovap, along with the
excess triethylsilane. Triethylsilane could be a very promising Cbz
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deprotection scheme moving forward, as it minimizes solvent and
reaction times, allowing for a more cost- and time-effective reaction.

2.3.3 Subsequent Amino Acid Couplings
Once the reaction conditions were maximized for the dimer, the
remaining amino acids were coupled mimicking these conditions. In
the trimer synthesis, the original deprotected dimer was dissolved in a
minimal amount of DCM (at the 2 gram scale, 13mL was used), as
there was no trifluoroacetate salt present to cause solvation problems.
This allowed for a much more concentrated solution, which
theoretically allowed for better and quicker coupling due to the closer
nature of the molecules present. Further down the synthesis scheme,
as the compound became larger, a little more DCM was needed
(15mL) for solvation, as the compound was actually absorbing the
DCM at smaller volumes. Once the smallest volumes of DCM were
realized for solvation, the yields increased dramatically, giving way to
anywhere between 74.5% (pentamer) to a high of 89.5% (hexamer)
yield.
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2.4 Future Considerations
Some future considerations for the complete synthesis of cHYD1
can be centered on the desire to lessen overall costs involved in the
synthesis. This includes the elimination of all columns, which are still
present in the recognition strand synthesis. The most ideal way to do
this would be to synthesis the entire peptide linearly and then cyclize,
rather than the current method of synthesizing the non-recognition
strand and recognition strand separately before coupling the two
strands together. The theory behind this linear synthesis suggestion
comes from the fact that the entire non-recognition strand produces a
solid at each step and a subsequent easy purification process via
simple recrystallization. If this is the case, it is theorized that the nonrecognition hexamer can help each new coupling have the same
overall nature, as we know the entire linear cHYD1 falls into this
category as well. Currently, the recognition strand synthesis involves
purification via a column after each coupling.
The other idea in lessening costs would be to lessen the amount
of reagents and solvents needed per step. In some instances,

®

T3P

might be able to be reduced from 2.0eq per coupling. Excess DIEA
could be kept to a minimum, and could eventually be transitioned to
the much cheaper similar base TEA. Also lowering coupling times
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might further drop overall costs when factoring in overall time spent
on total synthesis.

2.5 Experimental Procedure
2.5.1 Tert-butyl-2-aminoethylcarbamate

Fig. 2.4

Ethylenediamine (9.0 eq, 55.6 mL, 831 mmol) was dissolved in THF
(200 mL). A solution of Boc 2 O (1.0 eq, 20 g, 91.6 mmol) in THF (200
mL) was added dropwise at 0°C overnight. The resulting solution was
concentrated, dissolved in DCM (100 mL), and extracted with water
(3x20 mL). The water layers were back-extracted with DCM (100 mL),
and the organic layers were combined and concentrated, leaving a
yellow oil (14.52 g, 99%). m/z [M+H]+ 161.1.
TLC conditions: 9:1 methanol: ammonium hydroxide.

49

2.5.2 Tert-butyl (2-(methylsulfonamido)ethyl)carbamate

Fig. 2.5

Tert-butyl-2-aminoethylcarbamate (1.0 eq, 11.19 g, 69.8 mmol) was
dissolved in THF (100 mL). Triethylamine (1.2 eq, 11.68 mL, 83.8
mmol) was added. Methanesulfonyl chloride (1.0 eq, 5.41 mL, 69.8
mmol) was added at room temperature for one hour. The resulting
solution was concentrated, dissolved in ethyl acetate (EtOAc, 75 mL),
and extracted once with brine (10 mL) and twice with water (10 mL).
The organic layer was concentrated, resulting in an off-white solid
(15.11 g, 90.8%).
1

H NMR (400 MHz, CDCl 3 ) δ 5.50 (b, 1H), 5.25 (b, 1H), 3.27-3.24 (m,

2H), 3.22-3.18 (m, 2H), 2.93 (s, 3H), 1.40 (s, 9H).

13

C NMR (400

MHz, CDCl 3 ) ppm 156.74, 79.98, 43.67, 40.80, 40.35, 28.58.
TLC conditions: 100% ethyl acetate
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2.5.3 Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)acetate, BocLinker(OMe)

Fig. 2.6

Tert-butyl (2-(methylsulfonamido)ethyl)carbamate (1.0 eq, 15.11 g,
63.4 mmol) was dissolved in THF (100 mL). A solution of 60% sodium
hydride in toluene (1.0 eq, 2.54 g, 63.4 mmol) and THF (25 mL) was
added at 0°C, followed by methyl bromoacetate (1.0 eq, 5.83 mL,
63.4 mmol), and the solution was stirred for one hour. The solution
was quenched with water (10 mL). The resulting solution was
concentrated, dissolved in EtOAc (75 mL), and extracted five times
with water (10 mL). The organic layer was concentrated, and the
crude product was recrystallized in 1:1 EtOAc:Hexane (100 mL),
producing a white solid (14.96 g, 76.0%).
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1

H NMR (400 MHz, CDCl 3 ) δ 5.20 (b, 1H), 4.10 (s, 2H), 3.71 (s, 3H),

3.35-3.32 (m, 2H), 3.25-3.21 (m, 2H), 2.95 (s, 3H), 1.38 (s, 9H).

13

C

NMR (400 MHz, CDCl 3 ) ppm 170.54, 156.27, 79.72, 52.63, 48.57,
47.81, 39.79, 38.89, 28.55.
TLC conditions: 100% ethyl acetate.

2.5.4 Linker(OMe)-Lys(Boc)-NHCbz, Dimer

Fig. 2.7

Boc-Linker(OMe) (2.00 g, 6.44 mmol) was dissolved in DCM (10 mL).
Excess trifluoroacetic acid (TFA, 10 mL) was added and allowed to stir
for 20 mins. The resulting solution was concentrated, taking special
care to remove as much excess TFA as possible through multiple DCM
titurations (3x10 mL), of the resulting residue (2.02 g, 96.5%). The
deprotected product (1.0 eq, 2.02 g, 6.22 mmol) was dissolved in dry
DCM (40 mL) under argon. DIEA (2.5 eq, 2.57 mL, 16.0 mmol) was

52

added and Z-Lys(Boc)-OH (1.0 eq, 2.37 g, 6.22 mmol) was added.
Finally, a solution of 50% propanephosphonic anhydride in methylTHF
purchased from Archimica (®T3P, 2.0 eq, 7.92 mL, 12.4 mmol) was
added at 0°C and allowed to stir overnight. The resulting solution was
quenched with water (10 mL) for 1 hr, then concentrated and
dissolved in EtOAc (50 mL). Some crude product precipitated out, and
was filtered off. The filtrate was then extracted three times with water
(10 mL), the organic layer was concentrated, and the resulting crude
product was combined with the precipitate. The crude product was
then recrystallized in ether (10 mL) overnight, producing a white solid
(1.93 g, 54.6%). m/z [M+H]+ 573.1.
1

H NMR (400 MHz, CDCl 3 ) δ 7.30-7.26 (m, 5H), 7.00 (b, 3H), 5.74-

5.72 (d, 1H), 5.05 (s, 2H), 4.82 (b, 1H), 4.10 (s, 3H), 3.70 (s, 3H),
3.36-3.34 (m, 4H), 3.04 (b, 2H), 2.96 (s, 3H), 1.82-1.79 (m, 2H),
1.62-1.61 (m, 2H), 1.37 (s, 9H), 1.32-1.31 (m, 2H).

13

C NMR (400

MHz, CDCl 3 ) ppm 172.72, 170.51, 156.52, 136.49, 128.70, 128.55,
128.33, 79.23, 67.19, 55.21, 53.86, 52.69, 48.37, 47.32, 40.12,
39.61, 37.49, 32.12, 29.72, 28.63, 22.74.
TLC conditions: 100% ethyl acetate.
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2.5.5 Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer

Fig. 2.8

Linker(OMe)-Lys(Boc)-NHCbz (1.93 g, 3.38 mmol) was dissolved in
methanol (100 mL). Palladium (10%) carbon powder (0.4 g) was
added, and the solution was placed under H 2 pressure (55 psi)
overnight. The palladium carbon powder was filtered over
diatomaceous earth, and the resulting solution was concentrated,
forming a white solid. The deprotected product (1.0 eq, 1.48 g, 3.38
mmol) was dissolved in dry DCM (13 mL) under argon. DIEA (2.5 eq,
1.40 mL, 8.44 mmol) was added. Z-Leu-OH (1.0 eq, 0.896 g, 3.38
mmol) was added. Finally, a solution of 50% propanephosphonic
anhydride in methylTHF (®T3P, 2.0 eq, 4.30 mL, 6.75 mmol) was
added at 0°C and allowed to stir overnight. The resulting solution was
quenched with water (5 mL) for 1 hr, then concentrated and dissolved
in EtOAc (50 mL). Some crude product precipitated out, and was
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filtered off. The filtrate was then extracted three times with water (10
mL), the organic layer was concentrated, and the resulting crude
product was combined with the precipitate. The crude product was
then recrystallized in ether (10 mL) overnight, producing a white solid
(1.99 g, 86.3%). m/z [M+H]+ 686.1.
1

H NMR (400 MHz, cdcl 3 ) δ 7.36 – 7.30 (m, 4H), 6.95 (s, 1H), 6.74 (d,

J = 7.8, 1H), 5.40 (d, J = 6.3, 0H), 5.11 (s, 2H), 4.82 (s, 1H), 4.39 (t,
J = 14.9, 1H), 4.13 (s, 2H), 3.75 (d, J = 5.5, 3H), 3.47 (dd, J = 13.9,
7.0, 1H), 3.36 (d, J = 8.1, 3H), 3.05 (d, J = 6.0, 2H), 2.97 (s, 3H),
1.41 (s, 9H), 1.29 (d, J = 6.1, 2H), 1.19 (d, J = 7.0, 0H), 0.93 (d, J =
4.3, 6H).

13

C NMR (101 MHz, cdcl 3 ) δ 172.68, 172.08, 170.53,

136.35, 128.77, 128.25, 67.39, 54.19, 53.14, 52.69, 48.18, 47.30,
41.02, 40.36, 39.72, 37.18, 31.68, 29.49, 28.66, 24.93, 23.29, 22.84,
21.87.
TLC conditions: 100% ethyl acetate.
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2.5.6 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer

Fig. 2.9

Linker(OMe)-Lys(Boc)-Leu-NHCbz (1.99 g, 2.91 mmol) was dissolved
in methanol (100 mL). Palladium (10%) carbon powder (0.4 g) was
added, and the solution was placed under H 2 pressure (55 psi)
overnight. The palladium carbon powder was filtered over
diatomaceous earth, and the resulting solution was concentrated,
forming a white solid. The deprotected product (1.0 eq, 1.60 g, 2.91
mmol) was dissolved in dry DCM (10 mL) under argon. DIEA (2.5 eq,
1.20 mL, 7.27 mmol) was added. Z-Lys(Boc)-OH (1.0 eq, 1.11 g,
2.91 mmol) was added. Finally, a solution of 50% propanephosphonic
anhydride in methylTHF (®T3P, 2.0 eq, 3.70 mL, 5.81 mmol) was
added at 0°C and allowed to stir overnight. The resulting solution was
quenched with water (5 mL) for 1 hr, then concentrated and dissolved
in EtOAc (50 mL). Some crude product precipitated out, and was
filtered off. The filtrate was then extracted three times with water (10
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mL), the organic layer was concentrated, and the resulting crude
product was combined with the precipitate. The crude product was
then recrystallized in ether (10 mL) overnight, producing a white solid
(2.19 g, 82.7%). m/z [M+H]+ 914.3.
1

H NMR (400 MHz, cdcl 3 ) δ 7.32 (d, J = 14.9, 5H), 7.07 (s, 1H), 6.73

(s, 0H), 6.12 (d, J = 17.4, 0H), 5.12 – 5.03 (m, 2H), 4.84 (s, 1H),
4.71 (s, 6H), 4.16 (s, 2H), 3.75 (d, J = 6.1, 3H), 3.51 – 3.43 (m, 1H),
3.40 (d, J = 4.8, 3H), 3.15 – 3.02 (m, 4H), 3.00 (s, 3H), 1.39 (d, J =
10.4, 18H), 1.26 – 1.16 (m, 2H), 0.91 (dt, J = 20.0, 10.0, 6H).

13

C

NMR (101 MHz, cdcl 3 ) δ 170.63, 128.88, 105.10, 52.57, 47.18, 39.70,
28.71, 25.15, 23.33, 21.82.
TLC conditions: 100% ethyl acetate.
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2.5.7 Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz,
Pentamer

Fig. 2.10

Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz (2.19 g, 2.40 mmol) was
dissolved in methanol (100 mL). Palladium (10%) carbon powder (0.4
g) was added, and the solution was placed under H 2 pressure (55 psi)
overnight. The palladium carbon powder was filtered over
diatomaceous earth, and the resulting solution was concentrated,
forming a white solid. The deprotected product (1.0 eq, 1.87 g, 2.40
mmol) was dissolved in dry DCM (15 mL) under argon. DIEA (2.5 eq,
1.04 mL, 6.00 mmol) was added. Z-Leu- OH (1.0 eq, 0.638 g, 2.40
mmol) was added. Finally, a solution of 50% propanephosphonic
anhydride in methylTHF (®T3P, 2.0 eq, 3.06 mL, 4.79 mmol) was
added at 0°C and allowed to stir overnight. The resulting solution was
quenched with water (5 mL) for 1 hr, then concentrated and dissolved
in EtOAc (50 mL). Some crude product precipitated out, and was
filtered off. The filtrate was then extracted three times with water (10
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mL), the organic layer was concentrated, and the resulting crude
product was combined with the precipitate. The crude product was
then recrystallized in ether (10 mL) overnight, producing a white solid
(1.83 g, 74.5%). m/z [M+H]+ 1027.3.
TLC conditions: 100% ethyl acetate.

2.5.8
*Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NHCbz,
cHYD1 Non-Recognition Strand (cHYD1 NRS)

Fig. 2.11

Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz (1.83 g, 1.78 mmol)
was dissolved in methanol (100 mL). Palladium (10%) carbon powder
(0.4 g) was added, and the solution was placed under H 2 pressure (55
psi) overnight. The palladium carbon powder was filtered over
diatomaceous earth, and the resulting solution was concentrated,
forming a white solid. The deprotected product (1.0 eq, 1.59 g, 1.78
mmol) was dissolved in dry DCM (15 mL) under argon. DIEA (2.5 eq,
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0.736 mL, 4.45 mmol) was added. Z-Lys(Boc)-OH (1.0 eq, 0.678 g,
1.78 mmol) was added. Finally, a solution of 50% propanephosphonic
anhydride in methylTHF (®T3P, 2.0 eq, 2.27 mL, 3.56 mmol) was
added at 0°C and allowed to stir overnight. The resulting solution was
quenched with water (5 mL) for 1 hr, then concentrated and dissolved
in EtOAc (50 mL). Some crude product precipitated out, and was
filtered off. The filtrate was then extracted three times with water (10
mL), the organic layer was concentrated, and the resulting crude
product was combined with the precipitate. The crude product was
then recrystallized in ether (10 mL) overnight, producing a white solid
(2.00 g, 89.5%). m/z [M+Na]+ 1277.529.
TLC conditions: 100% ethyl acetate.
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CHAPTER THREE:
DEVELOPMENT OF A NOVEL hGH ANTAGONIST AND AGONIST

3.1 Introduction
Human growth hormone (hGH) is involved in many somatotropic
and lactogenic activities, as well as a host of cellular metabolic
mechanisms. Deficiencies of hGH can lead to reduction in lean body
mass, decreased skeletal and cardiac muscle mass and strength,
reduction of bone density, and in extreme cases, dwarfism. Overexpression can have equally devastating effects, possibly leading to
acromegaly, pituitary tumors, and certain type 1 diabetic conditions.
Produced in the pituitary gland, hGH is a 191 residue, 22kDA protein,
consisting of four distinct alpha helices ordered in an “up-up-downdown” conformation. Two mini-helices located in the loop between
helix 1 and 2 help in molecular stabilization and binding.
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Fig 3.1 PDB of 1HGU (1)

While studies have shown hGH to signal a variety of receptors
(2), its evolutionary purpose is to signal the human growth hormone
receptor (hGHR). hGHR is a member of sub-class 1 of the cytokine
receptor family(3), involving JAK2 activation via phosphorylation of the
kinase domain of JAK2 once hGHR is bound by the hormone, leading to
further signaling and the resultant biological effect (4, 5). It is a single
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transmembrane protein, consisting of 246 residues in its extracellular
domain (ECD). Signaling of the hGHR involves ligand-driven
homodimerization in a step-wise fashion. hGH binds to the ECD of one
hGHR at a region affectionately known as Site 1, involving portions of
helix 4, as well as parts of the two mini-helices between helix 1 and 2.
This hGH:hGHR complex then binds to a second hGHR in a region
known as Site 2 via portions of helix 1 and 3 of the hGH molecule and
a similar region of hGHR to its Site 1 binding region (6, 7). Site 1
binding has a much higher affinity than Site 2 binding, and involves a
much larger surface area (1300Å2 and 900Å2, respectively). This 1:2
(hGHR:hGH:hGHR) complex induces conformational changes within
the given hGHRs, allowing binding between the two receptors, which
ultimately leads to intracellular signaling (8, 9, 10). Interestingly
enough, Wells’ group (11) showed that binding was due to rate of
dissociation of the hormone to the receptor, rather than association.
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Scheme 3.1 Schematic of hGHR dimerization (12)
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Fig 3.2 PDB of hGHR 1 (red), hGHR2 (green), and hGH (white) (13)

Due to the homodimerization complex, and the fact that Site 1
binding has a higher affinity, disruption of the Site 2 binding region
has been the focus in leads towards antagonism of hGHR. A single site
mutation of hGH (G120R) proved to disrupt Site 2 binding, creating a
useful antagonist which has been used as the basis for most hGH
antagonist drug discoveries (14). Ultimately, increasing Site 1 binding
affinity in addition to disruption of Site 2 binding has led to “super-
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antagonism” of hGHR, which has led to the drug Pegvisomant (15, 16,
17).
Agonism of hGHR has been limited due to the asymmetrical
properties of hGH and its binding to the separate hGHRs. Monoclonal
antibodies have been used with limited success (18). Activity has
been shown in studies, but not to the degree that wild-type hGH
shows. Currently, only recombinant hGH molecules such as
Genotropin® (Pfizer) are on the market for drug administration,
showing a glaring need for smaller, more biologically effective
agonists.

3.2 Specific Aim
The specific aim of this proposal is to develop an hGH agonist.
In order to do so, the first step is to analyze the high affinity Site 1
binding region. Clackson, et al, (19) have shown that only a few
residues located in a small hydrophobic area (the “hot spot”) account
for more than 90% of the binding free energy. Two tryptophan
residues (W104 and W169) of the hGHR are involved in this “hot
spot”. They are located 4.54Å apart, sitting in a stacked formation.
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Fig 3.3 PDB of 1:1 hGH (white):hGHR (red). W104 and W169 of hGHR are
highlighted in yellow, representing the “hot spot”. R64, K172, and T175 are
highlighted in green (20).

Closer inspection of hGH binding shows that three residues (R64,
K172, and T175) of the hormone create the binding of the ligand to
these two tryptophan residues. R64 of hGH packs on top of W169 of
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hGHR via Van der Waals forces between the carbon skeleton of the
side-chain of R64 and the aromatic ring of W169. Some evidence
suggests R64’s guanido group interacts with D164 and E44 of hGHR.
K172 of hGH packs on top of W104 of hGHR similar to the
R64hGH:W169hGHR interaction. The γ-CH3 group of T175 of hGH sits
in the same plane as the aromatic ring of W104 of hGHR, creating a
Van der Waals force. There is some suggestion that the oxygen atom
of the hydroxyl group of T175 is a hydrogen bond acceptor to R43 of
hGHR, too.
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Fig 3.4 R64 of hGH (green) showing alkyl-aromatic stacking with W169 of hGHR
(yellow).
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Fig 3.5 K172 of hGH (green) showing alkyl-aromatic stacking with W104 of hGHR
(yellow).
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Fig 3.6 γ-CH 3 of T175 of hGH (green) in the same plane as W104 of hGHR (yellow).

Other residues involved in binding energy (I103, I105, P106,
D126, and I165 of hGHR, and L54, P61, F176, and R178 of hGH,
respectively) are actually intramolecular interactions for stabilization of
hGHR and hGH, respectively, allowing the binding to take place. The
distance between the α-carbons of K172 and T175 of hGH is 5.178Å,
while the distance between T175 and R64 of hGH is 9.979Å. The angle
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created from K172:T175:R64 is 94.1°. Ideally, using a peptide
scaffold mimicking these distances and angles would lead to a
compound which binds to the receptor.
Interestingly enough, a cyclized peptide scaffold combing
Robinson’s D-Pro/L-Pro beta-hairpin turn (21) with a
methylsulfonamido aminoethyl glycine residue on the other turn end
linking two five-residue strands (developed by the McLaughlin group)
produced almost identical distances and angles separating the αcarbons of residues 2, 5, and 6 (residues 2 and 5 are 9.729Å apart,
residues 5 and 6 are 5.167Å apart, and an angle of R2:R5:R6 is 90.9°
is created), while aligning the residues in the correct conformation.

Fig 3.7 Cyclized peptidic scaffold originally used to mimic hGH functional epitope
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Logic would dictate substituting an arginine residue for R2, a
threonine residue for R5, and a lysine residue for R6, therefore
mimicking the functional epitope of the native hGH molecule.
Unfortunately, due to a “hump” in the surface area of the binding
region, the resulting molecule cannot bind effectively, as modeling
projections show it protruding through the surface of the binding
region, and the resulting minimization confirms binding cannot be
attained.

Fig 3.8 Surface area showing “hump” around the “hot spot”, W104 and W169
(yellow).
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Using this scaffold, however, minimization shows there to be
enough of a natural curvature within the molecule to fit around the
surface area “hump”, with residues 3, 5, 6, and 8 being in position to
be directed around the two tryptophan residues of the receptor. When
substituting R3 with serine, R5 with lysine, R6 with leucine, and R8
with lysine, minimization and modeling shows binding of the molecule
to the receptor in a similar fashion to hGH binding.
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Fig 3.9 Proposed cyclized peptide molecule (grey) bound to hGHR (red). W104 and
W169 of hGHR (yellow) are shown.
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The hydrogen of the hydroxyl-group of S3 forms a hydrogen
bond with the main-chain carbonyl oxygen of G168 of the receptor
(directly next to W169). The δ-methyl groups of L6 are positioned in
the same plane as both tryptophan rings of the receptor, suggesting
similar binding as T175 of hGH with some possible additive effects
(another methyl group joining in with Van der Waals forces to W169
along with the aforementioned W104). Most importantly, K5 and K8
show alkyl-aromatic stacking with W169 and W104, respectively,
mimicking hGH binding. One hydrogen of the amine group on the
side-chain of K5 also forms a hydrogen bond with the carbonyl-oxygen
of E44 of the receptor, further strengthening binding, and matching a
previously suggested (but unconfirmed) interaction of the guanido
groups of R64 of hGH to E44 of hGHR.
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Fig 3.10 K8 (grey) showing alkyl-aromatic stacking on W104 of hGHR (yellow).
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Fig 3.11 K5 (grey) showing alkyl-aromatic stacking on W169 of hGHR (yellow).

There are also a couple unexpected hydrogen-bonding regions
somewhat downfield of the “hot spot”. The carbonyl-oxygen of the
main-chain of the methylsulfonamido aminoethyl glycine forms a
hydrogen-bond with the hydrogen of the amino group on the side
chain of R217 of the receptor, while one of the carbonyl-oxygen’s of
the sulfono-group of the same residue forms a hydrogen-bond with the
hydrogen of the amino group on the side chain of N218 of the
80

receptor. This could lead to further stabilization of the binding of the
molecule.

Fig 3.12 Hydrogen-bonding shown (in yellow) between proposed cyclized peptide
molecule and hGHR.

To dimerize hGHR, thus creating biological activity, the first
thought would be to study Site 2 binding. However, recent studies
have shown that dimerized antagonists which have an affinity for Site
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1 but no affinity for Site 2 have shown hGHR activity (22, 23). This
suggests two Site 1 binding regions can dimerize the receptors
effectively.

Fig 3.13 Comparison of hGHR binding between hormone (A) and dimerized
antagonists (B) (23).

The idea then would be to link two Site 1 peptidic mimics
together, preferably with the correct length. This can be accomplished
by substituting R9 of the molecule with lysine, as its side-chain
extends away from the receptor at virtually a 90° angle. A subsequent
polyethylene glycol (PEG) segment (24) can be attached to the sidechain amine, linking two concurrent Site 1 peptidic mimics together.
In hGH binding, the dimerized receptors have a distance of roughly
22Å between Site 1 binding regions.

The distance from the side-chain

amine of K9 to the Site 1 binding region is roughly 12Å. One PEG
segment is 5Å, therefore only one is needed to link the two mimics,
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giving roughly a 29Å distance between binding regions. This distance
could be minimized further if needed, possibly by substituting cysteine
in the R9 position.

Fig 3.14 Proposed peptidic molecule including linker.
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Fig 3.15 Rendering of proposed molecule dimerizing hGHR.

3.3 Synthesis
Synthesizing the molecule would be done through typical Fmoc
solid-phase synthesis. Any residue of the scaffold can be initially
downloaded to Wang resin, although to make synthesis easier,
commercially available Fmoc-Lys(Boc)-Wang Resin would be used. K9
would need an allyl-protecting group on the side-chain, rather than a
Boc group. Synthesis of the linear chain would include Fmocdeprotection via 20% Piperidine/2%DBU in DMF, followed by residue
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coupling using HCTU/NMM in DMF for activation purposes. The
resulting linear chain would be cleaved from the resin using 20%
trifluoroethanol in DCM (so as to not cleave the allyl and Bocprotecting groups from the side chains), and then cyclization would be
performed via another coupling step using HCTU/NMM in DMF. The
allyl-protecting group of K9 would then be cleaved using 2 equivalents
of Pd(PPh 3 ) 4 in 37:2:1 CHCl 3 :Acetic Acid:NMM. The PEG monomer
would be coupled to the molecule next through another coupling using
2 equivalents of the peptide molecule, again via HCTU/NMM in DMF.
Finally, the resulting dimerized peptide would be subjected to 95:2:2:1
TFA:Water:Anisole:EDT for cleavage and scavenging of all protecting
groups.

3.4 Chemical Evaluation
To determine the purity of the resultant hGH agonist, highperformance liquid chromatography (HPLC) would be used, allowing a
gradient from 5% to 90% acetonitrile as the solution phase. Matrixassisted laser desorption ionization via a time-of-flight tube for mass
spectrometry (MALDI-TOF MS) would be used for molecular weight
verification. NMR and CD analysis could be used, if necessary, to
study structural integrity.
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3.5 Biological Evaluation
For comparison purposes, hGH and G120R (antagonist) cDNAs
would be cloned via the bacterial expression vector pET22b, and the
subsequent ligands would be purified. Frank’s group (23, 25) reports
the development of a line of cells named “C14 cells” which would be
used to determine signal transduction of the bound GHR. As noted,
they “are the result of a stable transfection of GHR- and JAK2-deficient
human fibrosarcoma cell line γ2A with the wild-type rabbit GHR and
mouse JAK2.” C14 cells would be treated with equivalent molar
concentrations of each ligand, SDS-PAGE would be used for resolution,
and immunoblotting would be conducted using anti-GHR (to show
downfield GHR conformational change) (26), anti-JAK2 and antiphospho-JAK2 (anti-pJAK2, to determine JAK2 activation via tyrosinephosphorylation), and anti-STAT5 and anti-phospho-STAT5 (antipSTAT5, to determine STAT5 activation via tyrosine-phosphorylation).
Densitometry can be used to determine relative potency of the
signaling at different concentrations of the ligand.
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3.6 Optimization
After careful consideration, it was determined that 5-atom turn
promoter opposite of the D-Pro/L-Pro turn in the proposed molecule
would be extremely difficult to synthesize. With a known synthetic
protocol already in place for the similar 6-atom turn promoter (as
referenced in Chapter 2), this promoter was used, giving the peptidic
scaffold represented in Fig 3.16.

Fig 3.16 New peptidic scaffold introducing 6-atom turn promoter

Using the molecular modeling software MacroModel in Maestro
v9.2 by Schrödinger, the extra methylene group in the new peptide
proved to be very beneficial. In comparing the new SKLK peptide to
its older counterpart, the new peptide included six to ten hydrogenbonds with the given receptor, none of which involved the new 6-atom
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turn promoter, whereas the older peptide only included four hydrogenbonds with the receptor, two of which involved the 5-atom turn
promoter. The older peptide had a relatively poor conformation,
involving only one intramolecular hydrogen-bond, and included no
secondary structure recognition by the software. In contrast, the
newer peptide had a very good conformation, preserving all six
intramolecular hydrogen bonds, and showing a beta-turn secondary
structure, the desired structure needed for this particular proteinprotein interaction between peptide and receptor. The new peptide
still sustained all the same Site 1 binding as the old peptide as well.

3.6.1 Peptide Docking Procedure Overview
In docking the peptides via MacroModel, the PDB 3HHR, Fig 3.2,
was used. Priming was used to fill the missing residues, one histidine
and one threonine away from the Site 1 binding region of each
respective receptor. Once the hormone was removed from the dimer
structure, Sitemap could not locate the convex hormone binding site of
Site 1, involving W104 and W169. Only binding of the stem regions of
the receptors to each other was recognized, which represents the final
dimerization of the receptors leading towards the biological effect
within the cell. This lack of recognition of the Site 1 binding site led to
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the manual placement of single cyclized peptides on both receptors.
Minimization and conformational searches were then performed with
the receptors rendered frozen. Placement of the peptides in places
other than the Site 1 binding site, as well as other peptides not
capable of binding to Site 1, floated away after minimizations, as
represented by Fig 3.17, while those that did bind stayed in the Site 1
binding region, as represented by Fig 3.18.

Fig 3.17 Peptide not binding to receptor during minimization
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Fig 3.18 Peptide binding to receptor after minimization
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3.6.2 Linker Optimization
In the proposed molecule, one PEG unit was determined to be of
use as a linker between the two cyclized peptides due to the relative
correct distance between Site 1 binding sites of the dimerized
molecule.

Fig 3.19 One polyethylene glycol unit, PEG

After some consideration, possible linker derivatives were
explored. One particular linker, 5-aminoisophthalic acid, was thought
to be of more use due to having the same relative distance as PEG yet
allowing for a more rigid conformation given its benzene ring. This
should theoretically allow for less free movement in space, allowing
the dimerized molecule to be in a more correct position for dual Site 1
bindings and ultimately saving free energy within the given system.
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Fig 3.20 5-aminoisophthalic acid, APA

A two-unit PEG system was also explored, mainly as a way to
see if the excess distance would be a factor in linker development.

Fig 3.21 Two polyethylene glycol units, PEG2

3.6.2.1 Linker Docking Procedure Overview
In each of the three linker-peptide complexes, the same
procedure was used via MacroModel. The peptides were created with
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both receptors in place, and the linkers were then attached via the
side-chain amine of K9 with the appropriate free carboxylates of the
corresponding linkers. Minimization was then performed on the linkers
only, with the receptors and peptides frozen. Once this was done,
minimization was then performed with the di-cyclized peptides with
the receptors frozen. A conformational search was then run on each of
the di-cyclized peptides, again with their respective receptors frozen.

Table 3.1 Peptide-Only Conformational Energies

Linker

Potential Energy (kJ/mol)

APA

-21998

PEG

-21042

PEG2

-20499

A conformational search was then run with the di-cyclic
peptide/dimerized receptor complex in large-scale low mode. Finally,
a minimization of each entire complex was performed.
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Table 3.2 Full Complex Minimization Energies

Linker

ΔG binding (kJ/mol)

APA

-582,739.217

PEG

-557,469.042

PEG2

-555,214.104

Interestingly enough, all three linkers seemed to be of relative
similar use, with no significant differences between them in their
respective total energies. This can also be seen in Fig 3.22, showing
the overlay of each of the di-cyclized peptides and their respective
linkers.

Fig 3.22 Overlay of di-cyclic peptides
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When compared to the binding of the hormone, the respective
dimerized complexes also share very similar characteristics. Fig 3.23
shows this perfectly, with the overlay of all four complexes and the
hormone being removed for aesthetic purposes.

Fig 3.23 Overlay of all with PDB 3HHR

3.6.3 APA Example
Docking of the di-cyclized peptide with the APA linker is shown in
Fig 3.24 via the “side view” and in Fig 3.25 via the “overhead view”.
This shows the secondary beta-turn structure being conserved after
binding with and dimerizing the receptors.
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Fig 3.24 “Side view” of di-cyclized peptide with APA linker

96

Fig 3.25 “Overhead view” of di-cyclized peptide with APA linker

The hydrogen-bonding between peptides and their respective
receptors are conserved as noted in Section 3.6. There are ten
hydrogen-bonds with the “major” receptor and six hydrogen-bonds
with the “minor” receptor, as noted in Table 3.3 and 3.4, respectively.
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Table 3.3 “Major” Receptor Hydrogen-Bonding (bb = backbone)
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Table 3.4 “Minor” Receptor Hydrogen-Bonding (bb = backbone)
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3.6.4 APA Synthesis and Linkage

Scheme 3.2 Schematic of APA Synthesis and Linkage
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The starting material that leads to the eventual synthesis of APA
and its subsequent linkage is the commercially available 5nitroisophthalic acid. After hydrogenation of the starting material, 5aminoisophthalic acid was formed. The free amine should be
protected, which was done via placement of the Boc group in the
presence of TEA in methanol.

3.6.4.1 Lysine Derivative Synthesis

Scheme 3.3 Fmoc-Lys-OAllyl Synthesis

In order to couple the APA linker to the side-chain amine of K9,
the lysine derivative must first be synthesized. The starting material
used was the commercially available Fmoc-Lys(Boc)-OH. This was first
treated with cesium carbonate in the presence of methanol in order to
promote O-alkylation, which was then performed via the introduction
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of allyl bromide in the presence of DMF. The pure product was then
treated with methanesulfonic acid in DCM, allowing for selective
deprotection of the side-chain amine. Originally, TFA was used for
deprotection. However, residual TFA caused coupling problems,
capping off the free amine when activator was introduced. This led to
the desire to use methanesulfonic acid as an alternative deprotection
source. DIEA was then used to neutralize the solution, allowing for
coupling to take place.

3.6.4.2 Coupling
The coupling of the APA linker to the now free amine of the sidechain of the main-chain protected K9 was then performed. This was
done with DIEA and

®

T3P in the presence of THF.

3.7 Future Considerations
Some future considerations involving the development of
antagonist and agonist hGH mimics could include a library of different
linkers. Ideally, these linkers would be of the same distance as PEG,
as that would mimic the closest length between Site 1 binding sites.
However, as mentioned above with the PEG2 results, this may not be
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necessary. Linker exploration could involve a host of different lengths
as well as rigidity. Linker synthesis could and should be optimized as
well, as the coupling step with the K9 residue at the moment is a
troubling step.
The other major consideration could and should be the inclusion
of an entire combinatorial peptidic library developed around the lead
scaffold. This would include both the “important” residues used for
binding as well as the “non-important” residues currently being
represented by the use of alanine, and a myriad of different turn
promoters. This could be done computationally or via quick trial-anderror through solid phase synthesis and biological testing.

3.8 Experimental Procedures
3.8.1 Antagonist Synthesis
The antagonist was developed through solid phase peptide
synthesis on Protein Technologies’ automated 12-vessel synthesizer
The Symphony®. Fmoc-Lys-OAllyl was attached to 2-chlorotrityl resin
by the side-chain free amine. Each amino acid synthesis step included
an NMP wash (3 times at 30 second intervals), Fmoc deprotection via
20% Piperidine/2% DBU in DMF (1 loop volume, 1.25 mL, at 2:30),
NMP wash (3 times at 30 second invervals), introduction of the amino
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acid (1 loop volume, 1.25 mL) and coupling agent HCTU (1 eq) and
NMM (4 eq) in DMF (1 loop volume, 1.25 mL, at 5:00 twice through),
followed by NMP wash (3 times at 30 second intervals).
When the linear chain was finished, cyclization was performed
on-resin. Allyl deprotection was performed via 2 equivalents of
Pd(PPh 3 ) 4 in 37:2:1 CHCl 3 :Acetic Acid:NMM in NMP (90 minutes).
Following NMP washes (3 times at 30 second intervals), HCTU (1 eq)
and NMM (4 eq) in NMP (60 minutes) are used to couple the Nterminal and C-terminal amino acids. After successful cyclization, the
peptide and subsequent side-chain protecting groups were cleaved
using 95:2:2:1 TFA:Water:Anisole:EDT (60 minutes).
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3.8.2 Agonist Synthesis
3.8.2.1 5-Aminoisophthalic Acid

Fig 3.26

Commercially available 5-nitroisophthalic acid (4.37 g, 20.70 mmol)
was dissolved in methanol (100 mL). Palladium (10%) carbon powder
(0.4 g) was added, and the solution was placed under H 2 pressure (55
psi) overnight. The palladium carbon powder was filtered over
diatomaceous earth, and the resulting solution was concentrated,
forming a white solid (3.75 g, quant).
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3.8.2.2 5-((tert-butoxycarbonyl)amino)isophthalic acid

Fig 3.27

5-aminoisophthalic acid (1.0 eq, 2.28 g, 12.6 mmol) was dissolved in
methanol (40 mL). TEA (3.0 eq, 5.25 mL, 37.7 mmol) was added,
followed by Boc 2 O (1.1 eq, 3.02 g, 13.8 mmol). The reaction was
stirred overnight at room temperature. Concentrated HCl (10 mL) was
added, and the milky white solution was then poured over stirred
water (400 mL). The precipitate was filtered off, producing a pure
white solid product (2.02g, 57.1%). m/z [M+Na]+ 304.0.
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3.8.2.3 Fmoc-Lys(Boc)-OAllyl

Fig 3.28

Commercially available Fmoc-Lys(Boc)-OH (1.0 eq, 5.0 g, 10.7 mmol)
was dissolved in methanol (15 mL). Cesium carbonate (0.5 eq, 1.74
g, 5.34 mmol) was added, and the mixture was stirred at 0°C for 10
minutes. The reaction was concentrated and left under high vacuum
for 15 minutes. The product was dissolved in DMF (20 mL), and allyl
bromide (5.0 eq, 4.62 mL, 53.4 mmol) was added. The reaction was
stirred overnight at room temperature. After concentration, the
product was recrystallized in a 9:1 hexane: ethyl acetate mixture,
producing a white solid precipitate (5.25 g, 96.7%).
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3.8.2.4 hGH Linker

Fig 3.29

Fmoc-Lys(Boc)-OAllyl (1.0 eq, 0.503 g, 0.99 mmol) was dissolved in
dry DCM (8 mL). Methanesulfonic acid (4.0 eq, 0.257 mL, 3.96 mmol)
was added, and the reaction was stirred at room temperature for 20
minutes. After confirmation of Boc deprotection via TLC (100% ethyl
acetate) DIEA (5.0 eq, 0.812 mL, 4.94 mmol) was added to the stirred
mixture. 5-((tert-butoxycarbonyl)amino)isophthalic acid (0.3 eq,
0.083 g, 0.30 mmol) was added. More DIEA (1.0 eq, 0.163 mL, 0.99
mmol) was added. Finally, a solution of 50% propanephosphonic
anhydride in methylTHF purchased from Archimica (®T3P, 0.6 eq, 0.38
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mL, 0.59 mmol) was added at 0°C, and the mixture was allowed to stir
overnight. The resulting solution was quenched with water (5 mL),
concentrated, and dissolved in EtOAc (20 mL). The organic layer was
extracted three times with water (5 mL), dried over sodium sulfate,
and concentrated. The crude product was purified via
chromatography, with the product eluting at a ratio of 1:1
hexane:ethyl acetate, producing a clear solid (0.300 g, 57.1%). m/z
[M+H]+ 1062.4.

3.8.2.5 Agonist
The agonist was developed through solid phase peptide
synthesis on Protein Technologies’ automated 12-vessel synthesizer
The Symphony®. hGH linker was first deprotected with TFA (10 eq) in
DCM (5 mL). The free amine was then attached to 2-chlorotrityl resin.
Each amino acid synthesis step included an NMP wash (3 times at 30
second intervals), Fmoc deprotection via 20% Piperidine/2% DBU in
DMF (1 loop volume, 1.25 mL, at 5 minutes), NMP wash (3 times at 30
second invervals), introduction of the amino acid (2 loop volumes,
2.50 mL) and coupling agent HCTU (1 eq) and NMM (4 eq) in DMF (2
loop volumes, 2.50 mL, at 30 minutes twice through), followed by NMP
wash (3 times at 30 second intervals).
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When the linear chains were finished, cyclization was performed
on-resin. Allyl deprotection was performed via 4 equivalents of
Pd(PPh 3 ) 4 in 37:2:1 CHCl 3 :Acetic Acid:NMM in NMP (90 minutes).
Following NMP washes (3 times at 30 second intervals), HCTU (2 eq)
and NMM (8 eq) in NMP (60 minutes) are used to couple the Nterminal and C-terminal amino acids. After cyclization, the peptide
and subsequent side-chain protecting groups were cleaved using
95:2:2:1 TFA:Water:Anisole:EDT (60 minutes).
Unfortunately, this synthesis failed. An alternative route was
then explored. More antagonist was synthesized as mentioned in
Section 3.8.1, with the side-chain amines of the lysines at positions 5
and 8 being protected with a Cbz group, producing a compound
referred to as Antagonist-Z. Antagonist-Z (2.0 eq, 11.24 mg, 7.11
µmol) was dissolved in THF (1 mL). DIEA (5.0 eq, 2.94 µL, 17.8 µmol)
was added. 5-((tert-butoxycarbonyl)amino)isophthalic acid (1.0 eq,
1.00 mg, 3.56 µmol) was added. Finally, a solution of 50%
propanephosphonic anhydride in methylTHF purchased from Archimica
(®T3P, 3.0 eq, 6.79 µL, 10.67 µmol) was added, and the reaction was
stirred at room temperature for 3 days. After workup and
deprotection, however, we were unable to observe the product via
mass spectrometry.
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APPENDIX A: SELECTED 1H AND

13

C NMR SPECTRA

Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 1H NMR
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Tert-butyl (2-(methylsulfonamido)ethyl)carbamate
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13

C NMR

Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)acetate, BocLinker(OMe) 1H NMR
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Methyl 2-(N-(2-(tertbutoxycarbonylamino)ethyl)methylsulfonamido)acetate, BocLinker(OMe) 13C NMR
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer 1H NMR
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer
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13

C NMR

Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer 1H NMR
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Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer
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13

C NMR

Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer 1H NMR

122

Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer
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13

C NMR

APPENDIX B: SELECTED MASS SPECTRA

Tert-butyl-2-aminoethylcarbamate MS Data

124

Tert-butyl (2-(methylsulfonamido)ethyl)carbamate MS Data
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Linker(OMe)-Lys(Boc)-NHCbz, Dimer MS Data
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Linker(OMe)-Lys(Boc)-Leu-NHCbz, Trimer MS Data
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NHCbz, Tetramer MS Data
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NHCbz, Pentamer MS
Data
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Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NHCbz,
cHYD1 Non-Recognition Strand (cHYD1 NRS) MS Data
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5-Aminoisophthalic Acid MS Data
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5-((tert-butoxycarbonyl)amino)isophthalic acid MS Data
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Fmoc-Lys(Boc)-OAllyl MS Data

133

hGH Linker MS Data
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APPENDIX C: LIST OF ABBREVIATIONS

Ala = Alanine
APA = 5-Aminoisophthalic Acid
Arg = Arginine
Asn = Asparagine
Asp = Aspartic Acid
ATP = Adenosine Triphosphate
Boc = tert-Butyloxycarbonyl
Boc 2 O = Di-tert-butyl Dicarbonate
CAM-DR = Cell Adhesion Mediated Drug Resistance
Cbz = Carboxybenzyl
CD = Circular Dichroism
DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC = N,N’-Dicyclohexylcarbodiimide
DCM = Dichloromethane
DIEA = N,N-Diisopropylethylamine
DMF = N,N-Dimethyl Formamide
DNA = Deoxyribonucleic acid
ECD = Extracellular Domain
EtOAc = Ethyl Acetate
Fmoc = 9-Fluorenylmethyloxylcarbonyl
FN = Fibronectin
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Gln = Glutamine
Glu = Glutamic Acid
Gly = Glycine
HCTU = N,N,N′,N′-Tetramethyl-O-(6-chloro-1H-benzotriazol-1yl)uronium hexafluorophosphate
hGH = Human Growth Hormone
hGHR = Human Growth Hormone Receptor
HOBT = 1-Hydroxybenzotriazole
HPLC = High Performance Liquid Chromatography
Ile = Isoleucine
JAK2 = Janus Kinase 2
kDd = kilodalton
LCMS = Liquid Chromatography/Mass Spectrometry
Leu = Leucine
Lys = Lysine
MALDI-TOF-MS = Matrix Assisted Laser Desorption Ionization – Time
of Flight- Mass Spectrometry
MDM2 = Murine Double Minute
MDR = Multi-Drug Resistance
MeOH = Methanol
MM = Multiple Myeloma
MRD = Minimal Residual Disease
MSA = Methanesulfonic Acid
NMM = N-Methylmorpholine
NMP = N-Methylpyrrolidone
NMR = Nuclear Magnetic Resonance
Pd = Palladium
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PDB = Protein Data Bank
PEG = Polyethylene Glycol
Pro = Proline
RGD = Arg-Gly-Asp
SAR = Structure-Activity Relationship
Ser = Serine
SPPS = Solid Phase Peptide Synthesis
STAT5 = Signal Transducer and Activator of Transcription 5
®

T3P = Propylphosphonic Anhydride

TEA = Triethylamine
TFA = Trifluoroacetic Acid
THF = Tetrahydrofuran
TLC = Thin Layer Chromatography
Trp = Tryptophan
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